Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049127 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
A Phase 1 study of Adult Anaplastic Oligodendroglioma and Adult Mixed Glioma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT00049127 is a Phase 1 study of Adult Anaplastic Oligodendroglioma and Adult Mixed Glioma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 64 participants, above the 49-participant average among 7 other Adult Anaplastic Oligodendroglioma trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00049127, a Phase 1 study of Adult Anaplastic Oligodendroglioma and Adult Mixed Glioma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Imatinib Mesylate
Study Locations (20)
Illinois
- Rush - Copley Medical Center - Aurora
- Bromenn Lifecare Center - Bloomington
- Saint Joseph Medical Center - Bloomington
- Graham Hospital Association - Canton
- Memorial Hospital - Carthage
- Eureka Hospital - Eureka
- Galesburg Cottage Hospital - Galesburg
- Illinois CancerCare Galesburg - Galesburg
- Western Illinois Cancer Treatment Center - Galesburg
- Mason District Hospital - Havana
- Hopedale Medical Complex - Hospital - Hopedale
- Joliet Oncology-Hematology Associates Limited - Joliet
- Kewanee Hospital - Kewanee
- Mcdonough District Hospital - Macomb
- Garneau, Stewart C MD (UIA Investigator) - Moline
- Porubcin, Michael MD (UIA Investigator) - Moline
- Sharis, Christine M MD (UIA Investigator) - Moline
Arizona
- Mayo Clinic in Arizona - Scottsdale
Connecticut
- Saint Francis Hospital and Medical Center - Hartford
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2003-06 |
| Est. Completion | 2019-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049127
The ClinicalTrials.gov registry entry for NCT00049127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 49-participant average among 7 other Adult Anaplastic Oligodendroglioma trials with a reported enrollment target (31% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Adult Anaplastic Oligodendroglioma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00049127 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00049127 about?
NCT00049127 is a clinical study titled "Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor". This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of tumor cells by blocking the ...
What is the current status of trial NCT00049127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2003-06. Estimated completion is 2019-09-01.
What conditions does trial NCT00049127 study?
This clinical trial studies the following conditions: Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm, Adult Oligodendroglioma.
What interventions are being tested in trial NCT00049127?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT00049127?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00049127 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Anaplastic Oligodendroglioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
COMPLETED · Phase 1
-
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
COMPLETED · Phase 1
-
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
COMPLETED · Phase 1
-
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.